PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.23%
Positive EBIT growth while AVXL is negative. John Neff might see a substantial edge in operational management.
22.23%
Positive operating income growth while AVXL is negative. John Neff might view this as a competitive edge in operations.
18.34%
Positive net income growth while AVXL is negative. John Neff might see a big relative performance advantage.
32.95%
Positive EPS growth while AVXL is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
32.95%
Positive diluted EPS growth while AVXL is negative. John Neff might view this as a strong relative advantage in controlling dilution.
21.91%
Share count expansion well above AVXL's 1.98%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
21.91%
Diluted share count expanding well above AVXL's 5.72%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
46.02%
OCF growth above 1.5x AVXL's 26.30%. David Dodd would confirm a clear edge in underlying cash generation.
46.06%
FCF growth above 1.5x AVXL's 26.30%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8783.56%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
85.25%
Positive OCF/share growth while AVXL is negative. John Neff might see a comparative advantage in operational cash viability.
76.39%
3Y OCF/share CAGR above 1.5x AVXL's 27.11%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
-13944.86%
Negative 10Y net income/share CAGR while AVXL is at 48.85%. Joel Greenblatt sees a major red flag in long-term profit erosion.
85.03%
Positive 5Y CAGR while AVXL is negative. John Neff might view this as a strong mid-term relative advantage.
64.22%
3Y net income/share CAGR 75-90% of AVXL's 83.80%. Bill Ackman might push for an operational plan to match or beat the competitor’s short-term growth.
5293.49%
10Y equity/share CAGR above 1.5x AVXL's 695.19%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
188.65%
5Y equity/share CAGR at 75-90% of AVXL's 250.66%. Bill Ackman might push for an improved ROE or share repurchase strategy to keep up.
367.41%
Below 50% of AVXL's 3739.27%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-15.58%
Negative asset growth while AVXL invests at 11.77%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-38.36%
We have a declining book value while AVXL shows 1.41%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-22.17%
Our R&D shrinks while AVXL invests at 66.78%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-22.47%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.